Developing measurements to evaluate intersectional stigma related to cancer and HIV
开发测量方法来评估与癌症和艾滋病毒相关的交叉耻辱
基本信息
- 批准号:10844755
- 负责人:
- 金额:$ 20.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-13 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS related cancerAccountingAddressAdherenceAdministrative SupplementAffectAfricaAfrica South of the SaharaAreaAttitude to HealthAwardBehaviorBehavioralCaringCessation of lifeCharacteristicsCognitiveComplexComprehensionDataDevelopmentDimensionsDiscriminationEarly DiagnosisEnrollmentEnsureEpidemiologyEthnic OriginExposure toFactor AnalysisFundingGender IdentityGeneral PopulationGoalsHIVHIV diagnosisHealthHealth behaviorHealthcareIncidenceIndividualInfectionInterventionInterviewInvestigationKenyaLabelLaboratoriesLinkMalignant NeoplasmsMalignant neoplasm of lungMeasurementMeasuresMental DepressionMental HealthMethodsMorbidity - disease rateOutcomeOutcome MeasureParentsParticipantPatientsPersonsPopulationPreventionProcessQuality of lifeRaceReportingResearchResource-limited settingRiskSamplingScreening for cancerSelf EfficacySocial supportStigmatizationStructureTarget PopulationsTechniquesUnited StatesValidationWorkadherence ratecancer diagnosiscareer developmentcommunity involvementdesignexperiencefollow-upimprovedinterestintersectionalitymembermortalitymultidisciplinaryparent grantpatient populationpatient subsetsresponsescreening servicessocial exclusionsocial stigmasociodemographicstooltreatment adherencetreatment servicesvirus related cancer
项目摘要
PROJECT SUMMARY
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as
“NOT-CA-23-036.” Sub-Saharan Africa (SSA) bears a disproportional burden of HIV globally. Additionally, the
risk for malignancy in this population far exceeds the general population with higher associated morbidity and
mortality. As the dual burden of HIV and cancer in the global population increases, investigation of the impact
of stigma on this population is crucial for improving health outcomes.
Stigma is a well-studied construct that occurs when individuals are recognized and labeled as “other”
due to various sociodemographic, behavioral, or health-related characteristics, and has been linked to poor
quality of life and health-related outcomes. Stigma associated with HIV and cancer diagnoses in particular
have been associated to poor mental health, low treatment adherence rates, and decreased healthcare
engagement. When an individual has multiple, co-occurring stigmatizing characteristics, they have the potential
for a more complex stigma experience, termed intersectional stigma. Individuals living with HIV and cancer
may experience stigma more prominently due to one dominant stigmatizing condition or may experience a
synergistic or multiplicative effect. Intersectional stigma has been measured via validated scales for constructs
such as race, ethnicity, gender identity, and behavior, but no scale exists to measure the intersectionality of
HIV and cancer stigma. The ability to measure the stigma experience in people living with HIV and cancer is
crucial for assessing its influence on health-related behaviors and for designing more targeted interventions.
As an administrative supplement to U54 CA254571, our overall goal is to initiate the development of a
scale that effectively measures intersectional stigma in patients with concurrent HIV and cancer diagnoses.
Our specific aims are: 1) To develop a preliminary pool of scale questions that capture key dimension of HIV
and cancer intersectional stigma. We will use both pre-existing and de-novo qualitative interviews and
quantitative data to develop this initial pool. 2) To involve community stakeholders and participants with HIV
and cancer in further refinement of the pool of scale questions. We will use techniques including member
checking and cognitive debriefing. 3) To complete preliminary item validation on a population subset of patients
living with both HIV and cancer.
To achieve these aims, we leverage a multidisciplinary team of leaders in stigma, scale development,
HIV-associated cancers, and epidemiology. We will develop an intersectional stigma scale for HIV and cancer
supported by our already existing laboratory for HIV and malignancies in the AMPATH network in western
Kenya, funded by parent grant U54 CA254571. Findings from this work are expected to lead to the
development of an intersectional stigma scale that will help to better characterize co-occuring, potentially
synergistic HIV and cancer stigma and ultimately allow us to develop more informed health interventions.
项目概要
本申请是为了响应特殊利益通知(NOSI)而提交的,该通知被确定为
“NOT-CA-23-036。”撒哈拉以南非洲 (SSA) 在全球范围内承受着不成比例的艾滋病毒负担。
该人群患恶性肿瘤的风险远远超过一般人群,且相关发病率较高
随着全球人口中艾滋病毒和癌症的双重负担增加,对其影响进行了调查。
消除这一人群的耻辱对于改善健康结果至关重要。
耻辱是一种经过充分研究的结构,当个体被识别并标记为“其他”时就会发生
由于各种社会人口、行为或健康相关特征,并与贫困有关
特别是与艾滋病毒和癌症诊断相关的生活质量和健康相关结果。
与心理健康状况不佳、治疗依从率低和医疗保健减少有关
当一个人具有多种同时出现的污名化特征时,他们就有潜力。
更复杂的耻辱经历,称为交叉耻辱感染艾滋病毒和癌症的个人。
由于一种主要的耻辱状况,可能会更明显地经历耻辱,或者可能会经历一种
交叉污名已通过经过验证的构建尺度进行了测量。
例如种族、民族、性别认同和行为,但没有尺度来衡量这些因素的交叉性
艾滋病毒和癌症耻辱 衡量艾滋病毒和癌症患者的耻辱经历的能力是。
对于评估其对健康相关行为的影响和设计更有针对性的干预措施至关重要。
作为 U54 CA254571 的行政补充,我们的总体目标是启动开发
该量表可有效衡量同时患有艾滋病毒和癌症诊断的患者的交叉耻辱感。
我们的具体目标是: 1) 开发一个初步的量表问题库,以捕获艾滋病毒的关键维度
我们将使用预先存在的和从头开始的定性访谈和癌症交叉耻辱。
2) 让社区利益相关者和艾滋病毒参与者参与进来
和癌症,我们将使用包括成员在内的技术来进一步细化量表问题。
3) 完成对患者群体子集的初步项目验证。
同时患有艾滋病毒和癌症。
为了实现这些目标,我们利用了一支由多学科领导者组成的团队,负责污名化、规模化发展、
艾滋病毒相关癌症和流行病学我们将制定艾滋病毒和癌症的交叉耻辱量表。
得到我们在西部 AMPATH 网络中现有的艾滋病毒和恶性肿瘤实验室的支持
肯尼亚,由家长赠款 U54 CA254571 资助。这项工作的结果预计将导致
制定交叉耻辱量表,将有助于更好地描述同时发生的、潜在的
艾滋病毒和癌症耻辱的协同作用,最终使我们能够制定更明智的健康干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Ddungu Kambugu其他文献
Andrew Ddungu Kambugu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Ddungu Kambugu', 18)}}的其他基金
Evaluating the Impact of Intersectional Stigma on Linkage to Cancer Care in HIV-Associated Kaposi's Sarcoma in East Africa
评估东非艾滋病毒相关卡波西肉瘤中交叉耻辱与癌症护理的影响
- 批准号:
10406121 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers
美国-东非艾滋病毒相关恶性肿瘤研究中心 (USEAHAMRC),致力于职业发展以及病毒相关癌症的预防、早期检测和有效护理联系
- 批准号:
10454919 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers
美国-东非艾滋病毒相关恶性肿瘤研究中心 (USEAHAMRC),致力于职业发展以及病毒相关癌症的预防、早期检测和有效护理联系
- 批准号:
10669166 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
A Mentored Research Experience in Investigating the Socio-geographic Expansion to Liberia of a Novel Campaign-based Public Health Approach to Cervical Cancer Prevention
调查基于运动的新型宫颈癌预防公共卫生方法向利比里亚的社会地理扩张的指导研究经验
- 批准号:
10846445 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers
美国-东非艾滋病毒相关恶性肿瘤研究中心 (USEAHAMRC),致力于职业发展以及病毒相关癌症的预防、早期检测和有效护理联系
- 批准号:
10084687 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers
美国-东非艾滋病毒相关恶性肿瘤研究中心 (USEAHAMRC),致力于职业发展以及病毒相关癌症的预防、早期检测和有效护理联系
- 批准号:
10215455 - 财政年份:2020
- 资助金额:
$ 20.24万 - 项目类别:
相似国自然基金
套期会计有效性的研究:实证检验及影响机制
- 批准号:72302225
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
- 批准号:72372064
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
兔死狐悲——会计师事务所同侪CPA死亡的审计经济后果研究
- 批准号:72302197
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
上市公司所得税会计信息公开披露的经济后果研究——基于“会计利润与所得税费用调整过程”披露的检验
- 批准号:72372025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332003
- 批准年份:2023
- 资助金额:166 万元
- 项目类别:重点项目
相似海外基金
HIV Genomic Aging Project in Oncology (HIV-GAP)
肿瘤学中的 HIV 基因组衰老项目 (HIV-GAP)
- 批准号:
10491212 - 财政年份:2021
- 资助金额:
$ 20.24万 - 项目类别:
HIV Genomic Aging Project in Oncology (HIV-GAP)
肿瘤学中的 HIV 基因组衰老项目 (HIV-GAP)
- 批准号:
10403025 - 财政年份:2021
- 资助金额:
$ 20.24万 - 项目类别:
HIV Genomic Aging Project in Oncology (HIV-GAP)
肿瘤学中的 HIV 基因组衰老项目 (HIV-GAP)
- 批准号:
10687211 - 财政年份:2021
- 资助金额:
$ 20.24万 - 项目类别:
Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
铂相关毒性的遗传易感性和生物标志物
- 批准号:
10653162 - 财政年份:2012
- 资助金额:
$ 20.24万 - 项目类别: